Targeting Extracellular NAMPT and TLR4 as a Therapy for Pulmonary Arterial HypertensionTechnology #ua17-159
Questions about this technology? Ask a Technology Manager
Title: Targeting Extracellular NAMPT and TLR4 as a Therapy for Pulmonary Arterial Hypertension
Invention: The invention is the targeting of nicotinamide phosphoribosyltransferase (NAMPT) for the treatment of pulmonary arterial hypertension.
Background: Pulmonary arterial hypertension is a progressive disease that leads to increased resistance and eventual right ventricular failure and death. Unfortunately, current therapies are severely limited. NAMPT is a novel therapeutic target because NAMPT increases resistance to cell death, cell proliferation, and smooth muscle cell survival. NAMPT may play an important role in the prevention of pulmonary vascular remolding.
- Clinical research tools
- Addresses an unmet need in the treatment of pulmonary arterial hypertension
- Research into pathology of pulmonary arterial hypertension can lead to novel therapies such as small molecule drugs